Vulvovaginal candidiasis | Top 5 novel treatment findings

Engineered endolysin targets bacterial vaginosis

The engineered endolysin PM-477 demonstrated a significant ability to kill Gardnerella species and dissolve biofilms in 14 out of 15 tested cases of bacterial vaginosis, without affecting the remaining healthy vaginal microbiome. This suggests a promising alternative to antibiotics for treating BV, particularly in patients with recurrent infections.

Study published: 2020-10-27

Combination therapy using four antifungal drugs improves outcomes in immunocompromised patients with Candidiasis.

The study demonstrated that drug combinations showed synergistic effects on the sensitivity of Candida isolates, providing a more effective alternative to monotherapy and addressing drug resistance issues.

Study published: 2022-02-28

Halova ovules improve vaginal symptoms in postmenopausal women.

92.74% of participants rated the clinical performance of Halova ovules as 'excellent' when used alone, and 95.71% when used with other medications, with significant reductions in vaginal dryness and dyspareunia.

Study published: 2023-06-13

Cerviron ovules relieve vaginitis symptoms in women aged 20 to 70

Cerviron ovules demonstrated effectiveness in relieving vaginal symptoms and restoring normal vaginal pH levels after 3 months of treatment, both as a standalone treatment and in conjunction with antibiotics.

Study published: 2023-05-21

Astodrimer Gel prevents bacterial vaginosis recurrence

Astodrimer 1% Gel was superior to placebo in preventing recurrence of bacterial vaginosis, with a lower recurrence rate (44.2% vs 54.3%) and longer time to recurrence. Subject-reported symptoms such as vaginal odor and discharge were also significantly lower in the Astodrimer group.

Study published: 2020-10-01